Home › T-Cell Lymphoma › Illinois
T-Cell Lymphoma clinical trials in Illinois
7 studies for T-Cell Lymphoma are looking for participants at sites in Illinois.
Cities in Illinois
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Loyola Center for Health at Burr Ridge, Burr Ridge
- Loyola Medicine Homer Glen, Homer Glen
- Loyola University Medical Center, Maywood
- and 1 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06724237Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Northwestern University, Chicago
- University of Illinois, Chicago
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- and 6 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04803201A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Registry for People With T-cell Lymphoma
- Northwestern Medicine (Data Collection), Chicago
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.